Guardion Health Sciences is directed by a Science Advisory Board with advice from a Medical Advisory Board consisting of practicing physicians. Both teams are committed to unraveling and validating the connections between health and nutrition and developing products based on these findings. Their joint goal is the integration of a medical model of nutritional therapy into clinical practice.
SCIENCE ADVISORY BOARD
The GHS Science Advisory Board is a product development and research team of esteemed experts in the fields of biochemistry, biophysics, and clinical nutrition. In addition to developing products based on scientific studies in the public domain, the Science Advisory Board conducts and publishes its own evidence and uses this evidence in the precise formulation of all GHS products. As an elite team of scientists and researchers, the Science Advisory Board brings unmatched experience and judgment to the field of nutraceuticals.
His current research continues to focus on the bioavailability of different macular carotenoid formulations and improved, non-invasive methods of measuring macular pigment density and cataract development.
Bone has published more than 40 scholarly articles in leading journals as well as a number of contributed chapters in books devoted to carotenoids, the health of the eye and the cumulative light distribution on the human retina. He has been the recipient of numerous research grants including continuous funding by the National Institutes of Health since 1984.
In 2010, he was invited to become a Fellow of the Association for Research in Vision and Ophthalmology (FARVO), the leading organization for vision and ophthalmology world-wide.
*Bone was just awarded The Presidential Award for achievement in macular pigment research and dedicated service to the carotenoid field.
Active projects in his lab at Florida International University include research to understand the development of the macular pigment in young eye, study of the bioavailability of carotenoids in supplement formulations, and animal models of carotenoid transport and metabolism.
He is the editor of a recently published book, Carotenoids: Physical, Chemical, and Biological Functions and Properties and an associate editor for Archives of Biochemistry and Biophysics. He and has served as the guest editor of three Highlight Issues on Carotenoids for that journal, including the recent December 1, 2010 Fourth Highlight Issue on Carotenoids. (3) Dr. Landrum has published over 50 research publications in prominent, peer reviewed journals and edited volumes. He is the co-owner of patents on supplement formulas and devices for measurement of the macular pigment with his colleague and collaborator, Richard A. Bone, Ph.D.
*Landrum was just appointed president of the International Carotenoid Society for the next 3 years.
(1) Richard A. Bone, John T. Landrum, Susan T. Mayne, Christina M. Gomez, Susan E. Tibor and Ewa E. Twaroska. Invest. Ophthalmol. Vis Sci. (2001) 42:235-240. Macular Pigment in Donor Eyes with and without AMD: A Case-Control Study.
(2) Landrum, J. T.; Bone, R. A.; Joa, H.; Sprague, K.; and Moore, L. Exp Eye Res. (1997) 65, 57-62. A One Year Study of the Macular Pigment: The Effect of 140 Days of Lutein Supplement.
(3) Landrum, J. T. (editor) Arch. Biochem. Biophys. (2010) 504, 1-161. Fourth Highlight Issue on Carotenoids
Don has served at the CEO level of leadership as the Commander of a directed energy research laboratory, Commander of three hospitals, and Commander of the combat medical brigade during the initial occupation of Iraq. As the first Iraq Theater Surgeon, he was the architect and implementer of all components of medical operations and support in Iraq during the first year of the war, which included coordinating reconstruction with the Ministries of Health, Defense and Higher Education, as well as managing an integrated health care system for over 350,000 coalition forces from 33 nations and thousands of enemy prisoners of war and terrorist detainees in Iraq. He was individually recognized as having been “directly responsible for saving countless lives, both Coalition and Host Nation.”
Don subsequently served as the Chairman of the Medical Education and Training Campus Executive Committee and was responsible for overseeing the execution of $1B in the development of a new state-of-the-art military medical training facility and the implementation of the largest Joint training integration in the history of the Department of Defense. In November 2008, Don was appointed by the Assistant Secretary of Defense for Health Affairs as the first Executive Director of the Joint Department of Defense (DoD) and Department of Veterans Affairs (VA) Vision Center of Excellence (VCE) and was responsible for overseeing the clinical care, research, prevention, treatment and rehabilitation of military eye injuries in the DoD and VA healthcare systems. Under his leadership, the VCE successfully established the first ever Joint DoD and VA integrated database and clinical registry.
From 2009-2013 Don was appointed to the National Advisory Eye Council for the National Eye Institute (NEI), part of the National Institute of Health. The council advises the NEI about conducting and supporting research, training, health information dissemination, and other programs that address blinding eye diseases and disorders, visual function mechanisms, sight preservation, and health needs of visually impaired individuals. Don is an active advocate for Visually Impaired Veterans and currently serves on the Board of the Blinded Veterans Association and the Prevention of Blindness Society of Metropolitan Washington.
Dr. Sponsel routinely performs innovative surgery upon a referral patient’s only functioning eye, on newborns with congenital glaucoma, and victims of ocular trauma. Dr. Sponsel has pioneered the design and placement of a new generation of retrobulbar tube shunts (JG 2014) and was among the fist American surgeons to perform artificial iris implantation (JCRS 2012). He has helped lead new multidisciplinary research effort to extend our understanding of the forces at work in ocular trauma using empirical testing and supercomputer modeling (IOVS 2011a-c, 2014). His recent clinical research work bridges the basic and clinical sciences, with the first published glaucoma filtering surgery case series to document statistically significant visual field improvement (BJO 2013), and a refined data analysis of clinical data confirming that the two eyes and brain work together to conserve the binocular visual field in patients with bilaterally stabilized advanced glaucoma (TVST 2014). The latter work has received worldwide recognition and may help redirect approaches to combat a range of age-related neurodegenerative disorders that utilize biochemical mechanisms for programmed cell death similar to those at work in chronic glaucoma.
Dr. Hendler was Clinical Professor (Voluntary) of Medicine, University of California, San Diego; attending physician (Internal Medicine) at Scripps Mercy Hospital, San Diego; Professor (Honorary) of Biochemistry, Universidad Autonoma de Baja California; and Editor-in-Chief of the international Journal of Medicinal Food (Mary Ann Liebert, Publisher).
In addition to the PDR for Nutritional Supplements, he had authored several award-winning books in the area of dietary supplementation, including The Doctor’s Vitamin and Mineral Encyclopedia and The Complete Guide to Anti-Aging Nutrients. He had also published more than 80 peer-reviewed papers and patents in the areas of biochemistry, molecular biology, immunology, cancer research, dermatology, and neurological research, among others.
He was Postdoctoral Fellow at the Salk Institute where his research contributed to the discovery of the fine structure of the chromosome and to the development of the first antiviral and retroviral drugs. Dr. Hendler serves on the Scientific Advisory Council of Archer Daniels Midland and was a member of the AARP Pharmacy Nutrition Advisory Board and the Scientific and Nutrition Subcommittee of the United States Olympic Committee.
He received his Ph.D. in biochemistry and molecular biology from Columbia University, his M.D. at the University of California, San Diego, and postdoctoral training at the Salk Institute.
Dr.Hendler passed away suddenly in November 2012. He was the founding head of GHS Science Advisory Board. Dr. Hendler supervised and completed all of the formulas for GHS in 2011. He remains the company’s spiritual and moral compass.
During 20 years of affiliation with this company, he played a key role in the development and clinical testing of organic supplemental selenium (high-selenium yeast, L-selenomethionine) as well as chromium picolinate. This work culminated in two clinical studies of fundamental importance – Dr. Larry Clark’s ten-year chemoprevention study in which Nutrition 21’s high-selenium yeast was found to cut the cancer death rate of healthy elderly volunteers by roughly 50, and Dr. Nancy Cheng’s Beijing diabetes study in which chromium picolinate, at 1000 mcg chromium daily, was shown to be as effective as standard drugs for improving glycemic control in type 2 diabetes. Mark F. McCarty continues to author numerous technical publications.
His latest research at NutriGuard focuses on formulating integrative regimens for cancer control and developing PhyCB or PhyCB-enriched spirulina extracts as nutraceuticals, as part of a “Full-Spectrum Antioxidant Therapy” strategy to minimize excessive oxidative stress linked to numerous pathologies.
MEDICAL ADVISORY BOARD
The GHS Medical Advisory Board is composed of clinicians who are active medical practitioners. Members of the Medical Advisory Board consult with the Scientific Advisory Board on the current standards of care. They objectively advise on trends, needs, and issues of concern within their specialties and help shape the direction of Guardion Health Sciences’ research and product development efforts.
Dr. Hovanesian has been invited to lecture to surgeons on five continents, produced numerous surgical teaching videos, and written dozens of articles. He is faculty member at the UCLA Jules Stein Eye Institute, a board-certified ophthalmologist, and an internationally recognized leader in the field of corneal, cataract, refractive, and laser surgery.
He is the chairman of the American Academy of Ophthalmology’s online cataract surgery education committee and an editorial board member for five other eye journals. He has been honored by the American Academy of Ophthalmology and the American Society of Cataract and Refractive Surgery for contributions to his field and has been recognized by Wyanoke Publishing as one of the 250 leading innovators in the field of cataract surgery.
Dr. William Trattler has been invited to lecture across the U.S. on various topics such as: corneal infections of the eye, ocular allergy, dry eye, laser vision correction and sutureless cataract surgery techniques. Dr. Trattler is a Volunteer Assistant Professor of Ophthalmology at the University of Miami’s Bascom Palmer Eye Institute. Dr. Trattler is board certified by the American Board of Ophthalmology and has been an author of many articles and abstracts.
Dr. Trattler received the “Outstanding Young Ophthalmologist Leadership Award” from the Florida Society of Ophthalmology (FSO) and was elected President of the Miami Ophthalmology Society for 2006. In March 2006, Dr. Trattler was selected as one of the top 50 opinion leaders in Ophthalmology, as voted by his peers in a National survey.
Dr. Ritch has co-authored or edited nine textbooks and over 1600 medical and scientific papers, book chapters, articles and abstracts. He has presented nearly 700 lectures worldwide, including 40 named lectures and has received over 40 awards.
Dr. Ritch has trained over 140 clinical and research fellows, many of whom occupy academic positions worldwide. The international training program that he established at the New York Eye and Ear Infirmary has hosted over 60 International Council of Ophthalmology fellows and more than 100 observers from over 40 countries. He has worked and lectured extensively at the international level and has organized many symposia and conferences both in the United States and abroad. He has dedicated much of his time internationally over the last 30 years, and has organized conferences and symposia, trained over 80 fellows, ICO fellows, and observers from Asia, helped to establish residency and teaching programs and has made fundamental contributions to the modernization of ophthalmology in Thailand, Malaysia, the Philippines, Laos, Myanmar and other countries in Asia, and in Latin America. There are Asian, Brazilian, and International Ritch Fellows Societies.
He serves on the Executive Board of the American Society of Ocular Trauma and the editorial boards of Retinal Physician and Ophthalmic Lasers, Surgery and Imaging. His research interests include new treatments for macular degeneration and diabetic retinopathy, along with innovations in diagnostic retinal imaging and vitreoretinal surgical instrumentation. Through collaboration with the University of Kent and Ophthalmic Technologies, (OTI) he helped develop the first combined OCT/SLO instruments including versions that featured UltraHigh Resolution, combined OCT/SLO with integrated ICG Angiography, and OCT/SLO with integrated Microperimetry. His Advanced Retinal Imaging Laboratory is dedicated to application of novel technologies to address clinical challenges, including High Frequency and 3-D Ultrasound, Macular Pigment Densitometry, Retinal and Choroidal Blood Flow Monitoring, Retinal Oximetry and Metabolic Imaging, as well as the extremes of Anatomic Imaging. In Collaboration with Medical College of Wisconsin, he has recently added Adaptive Optics Imaging to the Infirmary’s Einhorn Clinical Research Center, designed to provide easy access for patients in the Metropolitan Tri-state area to Single Cell Retinal Imaging.
He attended medical school at Wayne State University School of Medicine in his native Detroit, Michigan, completing his internship and residency at Sinai Hospital of Detroit and the Kresge Eye Institute.
He has been in private practice in the San Diego area since 1985 with an emphasis on cataract and refractive surgery.
Dr. Davies began implanting the Crystalens accommodating intraocular lens in 2003, shortly after FDA approval was granted, and has participated in numerous clinical trials, including the HD100 and Trulign Toric FDA trials. He is a consultant and clinical instructor for Bausch + Lomb Surgical, training eye surgeons in the use of this and other lens implant technologies.
He serves on the Medical Advisory Board of Bausch + Lomb Surgical, Inc., and is a consultant for Glaukos, Inc., Optovue, Inc., and Guardion Health Sciences. He also serves as an advisor to the Charity Vision Foundation.
He is a Fellow of the American College of Surgeons, the American Academy of Ophthalmology and the American Society of Cataract and Refractive Surgery.
Dr. Davies and his wife Becky are the proud parents of seven children and nine grandchildren.
Dr. Stephenson of Stephenson Eye Associates has been recognized by numerous institutions for her expertise including being named one of 250 in Premier surgeons list of leading Innovators for her contributions to cataract surgery and premium IOL’s and also in Who’s Who in Ophthalmology. She is continuously engaged in clinical research and studies to evaluate new technology and is at the forefront of research and development in the creation of specialized surgical instrumentation and techniques, as well as the development of the next generation of intra-ocular lenses. She passes on her knowledge through lecturing and instruction to ophthalmologists worldwide, and to ophthalmology residents, as an Associate Professor at the University of South Florida.
Dr. Stephenson has been recognized by numerous institutions for her expertise. She is at the forefront of research and development in the creation of specialized surgical instrumentation and techniques, Dr. Stephenson is also involved in the development of the next generation of intra-ocular lenses.
She is also the current president (2015-2017) of the American College of Eye Surgeons (ACES).
Dr. Shen Lee immigrated to Dallas, Texas from Beijing at age 15. Both of her parents graduated from China’s most prestigious medical school, Peking Union Medical College (PUMC). Her upbringing in medical academia helped to shape her own career in helping others with their sight. In addition to practicing at Vision Optique, Dr. Shen Lee also founded iTravelCE in 2010.
Unique in destination education, iTravelCE is a bridge between the Asian and the American/European optical industries. It brings optometrists to Asia for their continuing medical education and to gain a better understanding of the optical industry in Asia. Through iTravelCE, Dr. Bridgitte Shen Lee is a consultant and a speaker for various optical industry companies to introduce eye care
professionals in the U.S. and Asia to the latest innovations in ophthalmic lenses, contact lens, luxury eye wear, Digital Eye Health℠, Anti-Aging Eye Care℠ and Ocular Aesthetics℠ products.
Dr. Shen Lee enjoys raising her young daughters to be global citizens and volunteering her time and talent at schools and in the Houston community. She served on the Houston Miller Theatre Advisory Board, and she currently serves on the Houston Ballet Foundation Board of Trustees.
Dr. Andrews graduated from New York Medical College with honors in surgery, internal medicine, emergency medicine and radiology. He completed residency training at California Pacific Medical Center in San Francisco. Prior to that, he received his undergraduate degree in biology from the University of San Diego and attended La Salle University School of Medicine in Mexico City.
He is currently a clinical mentor at St. Vincent de Paul Clinic and is a member of the AMA, American College of Physicians and the Society for Innovative Medical Practice Design. In 2009, he was listed among San Diego’s Top Doctors by San Diego magazine.
In 1983, he joined the Navy as a midshipman at the U.S. Naval Academy to fly jets — and ended up going to medical school and doing a surgical internship. He then spent more than a year as a General Medical Officer at McMurdo Station in Antarctica, as part of the Naval Support Force Antarctica. He returned to complete neurosurgery residencies and a neurosurgery fellowship and spent six years as a Neurosurgeon at Naval Medical Centers in Maryland, San Diego and Germany and three years as the Head, Division of Neurosurgery at the Naval Medical Center, San Diego.
Dr. Wanebo is board certified by the American Board of Neurological Surgery and is a member of the American Association of Neurological Surgeons, the Congress of Neurological Surgeons, the North American Skull Base Society and the Joint AANS/CNS Section of Cerebrovascular Surgery. He has been a principle investigator or co-investigator of several studies funded by NIH, NINDS, the Congress of Neurological Surgeons, and other research institutions. In addition to being a sought-after speaker, he is widely published in peer-reviewed medical journals and medical texts and has served on numerous editorial boards as an ad hoc reviewer, most recently for Neurosurgery and Neuroradiology.
Guardion Health Sciences’ leaders bring decades of diverse experience and a history of success.
Mr. Favish founded Fotoball USA, a pioneer in retail licensed products and marketing, in 1984. In 1994, Mr. Favish transformed Fotoball into a publicly held company listed on the Nasdaq Stock Exchange with 200 employees. Fotoball was acquired in January 2004 by an industry leading NSE company.
Mr. Favish founded Guardion Health Sciences (GHS) in 2009 with a strong belief that the healthcare industry has not focused enough on a proactive model of wellness for an expanding and increasingly affluent market. Mr. Favish is a strong advocate of bringing research-validated technologies and solutions to the attention of the medical and patient markets.
Throughout his career, Mr. Favish has been a guest speaker at several leading universities and an advisor to companies in both the United States and Asia, advising them on branding, product development and marketing strategies.
On April 29, 2014, Mr. Weingarten was appointed to the Board of Directors of Cortex Pharmaceuticals, Inc. (“Cortex”), and was named Vice President and Chief Financial Officer of Cortex.
Mark was the Worldwide President of DDB’s healthcare business, where he was responsible for a global communications business spanning 40+ offices in over 36 markets. The business covered advertising, digital, integrated communications, HCP promotion, branding, naming, design, market shaping, med ed and scientific communications.
Mark has previously held senior positions at Publicis Healthcare Communications Group where he was responsible for the global sanofi-aventis business and at Interbrand where he was CEO of their global Healthcare business.
Mark moved to New York where he held senior positions at Robert A. Becker, Euro RSCG and Jordan McGrath Case & Partners, Euro RSCG and ultimately at Euro RSCG Worldwide Headquarters, where he helped devise and build their global healthcare business – Euro RSCG Life Worldwide (Now Havas Life).
Mark holds a BSc (Hons) in Pharmacy. He is a board member of the prestigious Galien Foundation and a board member of G3 Global Genomics Group. He is a member of the Royal Pharmaceutical Society of Great Britain and is a past Co-Chairman of New York Corporate Development for the American Diabetes Association.
Through his collaborations with thought leading doctors in cataract, refractive, retina and glaucoma specialties, Gordon brings a wealth of expertise and knowledge to the table. A passion for the technology, clinical and surgical application, and business environment of the industry, coupled with an in-depth understanding of the dynamics of the eyecare market and years of collaboration with his customers, all combine to provide Gordon with a rich skill set invaluable to his role as VP of Sales and Marketing for Guardion Health Sciences.